Although NAT2 is expressed in prostate epithelium and the liver [13], our results suggest that the expression of the NAT2 phenotype in the liver has greater metabolic influence on HAA carcinogens of prostate cancer than its expression in the prostate. The gene discussed is NAT2; the disease is prostate carcinoma.